Who are Zinecard's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Idamycin Pfs, Vepesid, Blenoxane, amifostine trihydrate, BNP7787.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dexrazoxane.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Zinecard — Competitive Intelligence Brief

Zinecard (DEXRAZOXANE) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cytoprotective Agent. Area: Oncology.

marketed Cytoprotective Agent DNA topoisomerase 2-alpha Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Zinecard (DEXRAZOXANE) — Pfizer. Zinecard works by binding to metal ions and preventing them from causing damage to DNA during anthracycline treatment.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Zinecard TARGET	DEXRAZOXANE	Pfizer	marketed	Cytoprotective Agent	DNA topoisomerase 2-alpha	1995-01-01
Idamycin Pfs	IDARUBICIN		marketed	Anthracycline Topoisomerase Inhibitor	DNA topoisomerase 2-alpha	1990-01-01
Vepesid	etoposide	Bristol-Myers Squibb K.K.	marketed	Topoisomerase Inhibitor [EPC]	DNA topoisomerase 2-alpha	1983-01-01
Blenoxane	BLEOMYCIN	Bristol-Myers Squibb	marketed	Cytoprotective Agent	Aspartyl/asparaginyl beta-hydroxylase	1973-01-01
amifostine trihydrate	amifostine trihydrate	City of Hope Medical Center	marketed	Cytoprotective agent
BNP7787	BNP7787	Alliance for Clinical Trials in Oncology	phase 3	Cytoprotective agent / Cisplatin protectant	Cisplatin (indirect; forms inactivating complex)

Recent regulatory actions (last 90 days)

2026-02-13 — Vepesid · FDA · approved · US · Bristol-Myers Squibb K.K.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cytoprotective Agent class)

Bristol-Myers Squibb · 1 drug in this class
Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Zinecard — Competitive Intelligence Brief. https://druglandscape.com/ci/dexrazoxane. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab